Aspen Neuroscience, Inc. 424B4final IPO prospectus

Executive Summary

Aspen Neuroscience develops patient-derived cell therapies for Parkinson’s disease and pediatric neurological disorders; it has no approved products or revenue. Its future rests on sasineprocel, designed to replace lost dopamine neurons, and on making individualized manufacturing reliable enough for wider treatment. Early clinical signals are encouraging but uncontrolled, while development spending pushed H1 2026 net loss to $(36.5)M. The $141M all-primary IPO implies a $436M market capitalization and gives buyers 32% ownership. Investors are funding a transition toward controlled Phase 3 testing—not commercialization—and must accept further financing needs before development is complete.

Business Model and Growth Drivers

Aspen’s proposed business is selling patient-specific cell therapies, initially sasineprocel for Parkinson’s disease. It retains worldwide commercial rights. Management estimates that ≈150,000 U.S. patients could qualify for cell-replacement surgery, but approval, reimbursement and adoption remain unproven.

Sasineprocel starts with a patient’s skin cells, reprograms them into stem cells and differentiates them into dopamine-neuron precursors for surgical delivery into the brain. Using the patient’s own cells is intended to avoid prolonged immunosuppression; that advantage and any disease-modifying effect are not established comparative outcomes. Production and testing take ≈20–21 weeks. A thaw-and-inject formulation reduced treatment-site preparation from three to four hours to ≈25 minutes, potentially broadening eligible treatment sites.

The open-label ASPIRO trial had treated 15 patients by 8/18/2026. At 18 months, four high-dose patients reported 2.7 additional daily hours of good symptom control; imaging also suggested increased dopamine activity. No graft rejection was reported, but one participant experienced serious procedure-related events, including an ischemic stroke. Small cohorts, varying follow-up and no control group prevent firm efficacy conclusions.

Aspen targets Phase 3 dosing in H2 2027 following further regulatory alignment. Automated manufacturing, expected ready in early 2027, targets more than 90% less manual labor but still needs validation and regulatory clearance. A second, gene-corrected microglia program for pediatric leukodystrophies is planned to enter studies supporting a clinical-trial application in H2 2027.

The Offering

• At $15.00, 9,375,000 primary shares generate the gross raise above, with no secondary sales. Implied valuation uses 29,078,600 post-offering shares. Including outstanding options and warrants gives 32,167,189 fully diluted shares and $483M capitalization before future awards and reserves. Revenue and earnings multiples are inapplicable.
• Estimated net proceeds are ≈$126M, or ≈$145M with full exercise of the 30-day, 1,406,250-share underwriters’ option. Aspen receives the money. Leerink Partners, Piper Sandler, Stifel, UBS and Oppenheimer underwrite the Nasdaq Global Select Market listing, ASPE.
• Proceeds plus existing resources allocate $110M to initiating and funding Phase 3, $8.0M to ASPIRO and $4.0M to microglia development, with the remainder for general purposes. They do not fund completion of either sasineprocel trial.
• Each IPO share is backed by $7.34 of net tangible assets after the IPO, a $7.66 gap to its purchase price. Existing holders paid a weighted-average $17.51 per share.
• Preferred conversion adds 17,971,324 common shares; insider-note forgiveness accounts for another 622,707. Conversion alone moves stockholders’ equity to $87.7M before offering proceeds; the after-IPO figures below include both events and net proceeds.
• The prospectus is dated 10/29/2026; delivery is expected on or about 11/2/2026. Substantially all existing securities face 180-day lock-ups ending 4/27/2027, after which up to 19,703,600 restricted shares may become sale-eligible, subject to applicable restrictions.

Key Financial Highlights

Amounts in $M. Balance-sheet columns are historical before the IPO; “After IPO” applies offering adjustments to 6/30/2026.

• Spending drivers: H1 2026 R&D increased 37%, including $4.05M more development and production costs, $2.17M more salaries and benefits, and $0.715M more stock-based compensation.
• Non-operating effects: FY2025 included a $4.55M write-down of Aspen’s investment in manufacturing partner Cell X—not debt Aspen owed—which widened losses without equivalent cash spending. Its near-stable value and higher interest income softened H1 2026’s net-loss increase.
• Equity bridge: Before-IPO equity excludes $339M of convertible preferred stock and reflects $265M of accumulated losses. Conversion reclassifies preferred capital into equity; forgiveness increases the accumulated deficit by $1.82M through noncash compensation.
• Funding horizon: Management projects resources into H2 2028, not trial completion. A new headquarters lease adds ≈$20.2M of future base rent beyond existing lease commitments.

Governance and Control

• Common stock has one vote per share. Officers, directors and major holders collectively are expected to own ≈44%; a classified board and supermajority removal requirements further constrain shareholder influence.
• Executive Chairman Faheem Hasnain’s agreement provides five potential awards, each initially based on 1% of post-offering fully diluted shares, subject to differing service, price and reduction conditions. Outstanding options total 3.07M shares, 9.5% of the fully diluted count, with computed IPO-price intrinsic value of $25.3M; accounting compensation uses grant-date values.
• Aspen forgave insider exercise-note balances in exchange for longer vesting. It expects a $1.8M incremental noncash charge in Q3 2026. Its related-person transaction review policy begins only at closing.

Risk Assessment

• Going concern and financing: Interim disclosures identify substantial doubt before financing; even after the IPO, development requires additional capital, exposing buyers to dilution or curtailed programs.
• Clinical concentration: Sasineprocel dominates the investment case, and uncontrolled observations may not survive sham-controlled testing.
• Manufacturing execution: Switching from manual production to automation requires comparability, while a single manufacturing facility and specialized suppliers create disruption exposure.
• Commercial acceptance: Premium pricing and brain surgery require both payer coverage and patient acceptance against established treatments and competing experimental therapies.
• Licensed technology: Losing foundational licenses or facing manufacturing-patent disputes could interrupt development or increase costs.
• Resale supply: The lock-up expiry could release a large existing-holder block alongside continuing equity-award dilution.

What to Watch

• Phase 3 execution: Planned H2 2027 dosing depends on regulatory agreement and trial preparation; later filings should show enrollment and dosing rather than repeated delays.
• Manufacturing readiness: Automation must reproduce clinical product quality; validation and regulatory acceptance would support scale, while failures could require more studies.
• Durability: Further ASPIRO data are expected in H1 2028; sustained functional gains with acceptable safety would strengthen—but not prove—the case.
• Financing runway: The projected H2 2028 funding horizon holds if spending and milestones remain aligned; earlier fundraising or program cuts would weaken it.